Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium

Psychiatry Research

Volumn 225, Issue 3, 2015, Pages 604-608

  Muti, Matteo ^a   Del Grande, Claudia ^a   Musetti, Laura ^a   Marazziti, Donatella ^a   Turri, Milo ^a   Cirronis, Marco ^a   Pergentini, Irene ^a   Corsi, Martina ^a   Dell'Osso, Liliana ^a   Corsini, Giovanni Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Biological marker; Bipolar disorder; Lithium; Purinergic system; Uric acid

Indexed keywords

CARBAMAZEPINE; LITHIUM; URIC ACID; VALPROIC ACID; LITHIUM DERIVATIVE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; BIPOLAR DISORDER; BLOOD; DRUG COMBINATION; MIDDLE AGED;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; SEX FACTORS; URIC ACID; VALPROIC ACID;

EID: 84922943464     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.11.038     Document Type: Article

References (51)

1. Akhondzadeh S., Safarcherati A., Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29(2):253-259.
2. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC, (Text Revision). fourth edition.
3. Anumonye A., Reading H.W., Knight F., Ashcroft G.W. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1968, 1(7555):1290-1293.
4. Akhondzadeh S., Milajerdi M.R., Amini H., Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disorder 2006, 8(5 Pt 1):485-489.
5. Barden N., Harvey M., Gagné B., Shink E., Tremblay M., Raymond C., Labbé M., Villeneuve A., Rochette D., Bordeleau L., Stadler H., Holsboer F., Müller-Myhsok B. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2006, 141B(4):374-382.
6. Brunstein M., Ghisolfi E., Ramos F.L., Lara D.R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. The Journal of Clinical Psychiatry 2005, 66(2):213-219.
7. Burnstock G. Historical review: ATP as a neurotransmitter. Trends in Pharmacological Sciences 2006, 27(3):166-176.
8. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiological Reviews 2007, 87(2):659-797.
9. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nature Reviews Drug Discovery 2008, 7(7):575-590.
10. Cade J.F.J. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949, 2(10):349-352.
11. Chung K.H., Huang C.C., Lin H.C. Increased risk of gout among patients with bipolar disorder: a nationwide population-based study. Psychiatry Research 2010, 180(2-3):147-150.
12. De Berardis D., Conti C.M., Campanella D., Carano A., Di Giuseppe B., Valchera A., Tancredi L., Serroni N., Pizzorno A.M., Fulcheri M., Gambi F., Sepede G., Moschetta F.S., Salerno R.M., Ferro F.M. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. Journal of Biological Regulators & Homeostatic Agents 2008, 22(3):195-200.
13. Del Grande C., Muti M., Musetti L., Pergentini I., Corsi M., Turri M., Soldani I., Corsini G.U., Dell'Osso L. Long-term treatment of bipolar disorder: how should we use lithium salts?. Rivista di Psichiatria 2012, 47(6):515-526.
14. El-Mallakh R.S., Jefferson J.W. Prethymoleptic use of lithium. The American Journal of Psychiatry 1999, 156(1):129.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2002, (ed. Biometrics Research), New York State Psychiatric Institute, New York.
16. Haj Mouhamed D., Ezzaher A., Neffati F., Douki W., Gaha L., Najjar M.F. Effect of cigarette smoking on plasma uric acid concentrations. Environmental Health and Preventive Medicine 2011, 16(5):307-312.
17. Johnson R.J., Sautin Y.Y., Oliver W.J., Roncal C., Mu W., Gabriela Sanchez-Lozada L., Rodriguez-Iturbe B., Nakagawa T., Benner S.A. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?. Journal of Comparative Physiology B 2009, 179(1):67-76.
18. Katz J.L., Weiner H. Psychosomatic considerations in hyperuricemia and gout. Psychosomatic Medicine 1972, 34(2):165-182.
19. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorder 2000, 2(3 Pt 1):180-190.
20. Kesebir S., Süner O., Yaylaci E.T., Bayrak A., Turan C. Increased uric acid levels in bipolar disorder: is it a trait or state?. Journal of Biological Regulators & Homeostatic Agents 2013, 27(4):981-988.
21. Kraepelin E. Manic-Depressive Insanity and Paranoia 1921, E. & S. Livingstone, Edinburgh.
22. Jinnah H.A. Lesch-Nyhan disease: from mechanism to model and back again. Disease Models & Mechanisms 2009, 2(3-4):116-121.
23. Lam D.D., Garfield A.S., Marston O.J., Shaw J., Heisler L.K. Brain serotonin system in the coordination of food intake and body weight. Pharmacological Biochemistry and Behavior 2010, 97(1):84-91.
24. Lara D.R., Belmonte-de-Abreu P., Souza D.O. Allopurinol for refractory aggression and self-inflicted behaviour. Journal of Psychopharmacology 2000, 14(1):81-83.
25. Lara D.R., Brunstein M., Ghisolfi E.S., Lobato M.I., Belmonte-de-Abreu P., Souza D.O. Allopurinol augmentation for poorly responsive schizophrenia. International Clinical Psychopharmacology 2001, 16(4):235-237.
26. Lara D.R., Cruz M., Xavier F., Souza D.O., Moriguchi E.H. Allopurinol for the treatment of aggressive behaviour in patients with dementia. International Clinical Psychopharmacology 2003, 18(1):53-55.
27. Lorenzi T.M., Borba D.L., Dutra G., Lara D.R. Association of serum uric acid levels with emotional and affective temperaments. Journal of Affective Disorders 2010, 121(1-2):161-164.
28. Lucae S., Salyakina D., Barden N., Harvey M., Gagné B., Labbé M., Binder E.B., Uhr M., Paez-Pereda M., Sillaber I., Ising M., Brückl T., Lieb R., Holsboer F., Müller-Myhsok B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Human Molecular Genetics 2006, 15(16):2438-2445.
29. Machado-Vieira R., Lara D.R., Souza D.O., Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. Journal of Clinical Psychopharmacology 2001, 21(6):621-622.
30. Machado-Vieira R., Lara D.R., Souza D.O., Kapczinski F. Purinergic dysfunction in mania: an integrative model. Medical Hypotheses 2002, 58(4):297-304.
31. Machado-Vieira R., Soares J.C., Lara D.R., Luckenbaugh D.A., Busnello J.V., Marca G., Cunha A., Souza D.O., Zarate C.A., Kapczinski F. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. The Journal of Clinical Psychiatry 2008, 69(8):1237-1245.
32. Machado-Vieira R., Henter I., Baumann J., Latov D., Wheeler-Castillo C., Zarate C.A. Novel therapeutic approaches for treating bipolar disorder. Bipolar Psychopharmacotherapy: Caring for the Patient 2011, 423-445. John Wiley & Sons, Ltd., New York. second edition. H.S. Akiskal, M. Tohen (Eds.).
33. Machado-Vieira R. Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania. Journal of Clinical Psychopharmacology 2012, 32(5):735-736.
34. Manowitz P., Amorosa L.F., Goldstein H.S., Carlton P.L. Uric acid level increases in humans engaged in gambling: a preliminary report. Biological Psychology 1993, 36(3):223-229.
35. McQuillin A., Bass N.J., Choudhury K., Puri V., Kosmin M., Lawrence J., Curtis D., Gurling H.M. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar- affective disorders. Molecular Psychiatry 2009, 14(6):614-620.
36. Moeller F.G., Barratt E.S., Dougherty D.M., Schmitz J.M., Swann A.C. Psychiatric aspects of impulsivity. The American Journal of Psychiatry 2001, 158(11):1783-1793.
37. Muti M., Del Grande C., Musetti L., Marazziti D., Pergentini I., Corsi M., Turri M., Corsini G.U., Dell'Osso L. Prescribing patterns of lithium or lithium+valproate in manic and mixed episodes: a naturalistic study. International Clinical Psychopharmacology 2013, 28(6):305-311.
38. Pacher P., Nivorozhkin A., Szàbo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacological Reviews 2006, 58(1):87-114.
39. Perheentupa J., Raivio K. Fructose-induced hyperuricemia. Lancet 1967, 2(7515):528-531.
40. Powell C.R., Stoller M.L., Schwartz B.F., Kane C., Gentle D.L., Bruce J.E., Leslie S.W. Impact of body weight on urinary electrolytes in urinary stone formers. Urology 2000, 55(6):825-830.
41. Ring H.A., Heller A.J., Marshall W.J., Johnson A.L., Reynolds E.H. Plasma uric acid levels in patients receiving anticonvulsant monotherapy. Epilepsy Research 1991, 8(3):241-244.
42. Rösler M., Fischer R., Ammer R., Ose C., Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience 2009, 259(2):120-129.
43. Salvadore G., Viale C.I., Luckenbaugh D.A., Zanatto V.C., Portela L.V., Souza D.O., Zarate C.A., Machado-Vieira R. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(6):819-821.
44. Schretlen D.J., Ward J., Meyer S.M., Yun J., Puig J.G., Nyhan W.L., Jinnah H.A., Harris J.C. Behavioral aspects of Lesch-Nyhan disease and its variants. Developmental Medicine & Child Neurology 2005, 47(10):673-677.
45. Soeiro-de-Souza M.A., Andreazza A.C., Carvalho A.F., Machado-Vieira R., Young L.T., Moreno R.A. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. The International Journal of Neuropsychopharmacology 2013, 16(7):1505-1512.
46. Spearing M.K., Post R.M., Leverich G.S., Brandt D., Nolen W. Modification of the Clinical Global Impressions (CGI) scale for the use in bipolar illness (BP): the CGI-BP. Psychiatry Research 1997, 73(3):159-171.
47. Sutin A.R., Cutler R.G., Camandola S., Uda M., Feldman N.H., Cucca F., Zonderman A.B., Mattson M.P., Ferrucci L., Schlessinger D., Terracciano A. Impulsivity is associated with uric acid: evidence from humans and mice. Biological Psychiatry 2014, 75(1):31-37.
48. Suwazono Y., Kobayashi E., Uetani M., Miura K., Morikawa Y., Ishizaki M., Kido T., Nakagawa H., Nogawa K. The -1438A/G polymorphism in the 5-hydroxytryptamine receptor 2A gene is related to hyperuricemia, increased gamma-glutamyl transpeptidase and decreased high-density lipoprotein cholesterol level in the Japanese population: a prospective cohort study over 5 years. International Journal of Molecular Medicine 2006, 17(1):77-82.
49. Vieta E., Morralla C. Prevalence of mixed mania using 3 definitions. Journal of Affective Disorder 2010, 125(1-3):61-73.
50. Wen S., Cheng M., Wang H., Yue J., Wang H., Li G., Zheng L., Zhong Z., Peng F. Serum uric acid levels and the clinical characteristics of depression. Clinical Biochemistry 2012, 45(1-2):49-53.
51. Zarate C.A., Manji H.K. Bipolar disorder: candidate drug targets. Mount Sinai Journal of Medicine 2008, 75(3):226-247.